Viracta Therapeutics (FRA:RYI) Total Liabilities : €27.83 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Total Liabilities?

Viracta Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €27.83 Mil.

Viracta Therapeutics's quarterly Total Liabilities increased from Sep. 2023 (€34.13 Mil) to Dec. 2023 (€35.19 Mil) but then declined from Dec. 2023 (€35.19 Mil) to Mar. 2024 (€27.83 Mil).

Viracta Therapeutics's annual Total Liabilities increased from Dec. 2021 (€12.55 Mil) to Dec. 2022 (€32.93 Mil) and increased from Dec. 2022 (€32.93 Mil) to Dec. 2023 (€35.19 Mil).

Viracta Therapeutics Total Liabilities Historical Data

The historical data trend for Viracta Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Total Liabilities Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Liabilities

77.68

12.55

32.93

35.19

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial												32.38	33.30	34.13	35.19	27.83

Viracta Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Viracta Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	35.188	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	35.19

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	51.987	-	16.799
	=	35.19

Viracta Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	27.834	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	27.83

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	38.027	-	10.194
	=	27.83

Viracta Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (FRA:RYI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (FRA:RYI) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

VIRX:USA RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.